Review



human plasma  (Innovative Research Inc)


Bioz Verified Symbol Innovative Research Inc is a verified supplier
Bioz Manufacturer Symbol Innovative Research Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Innovative Research Inc human plasma
    Human Plasma, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human plasma/product/Innovative Research Inc
    Average 94 stars, based on 1 article reviews
    human plasma - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    human plasma  (Innovative Research Inc)
    94
    Innovative Research Inc human plasma
    Human Plasma, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human plasma/product/Innovative Research Inc
    Average 94 stars, based on 1 article reviews
    human plasma - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    plasma cell isolation kit ii  (Miltenyi Biotec)
    92
    Miltenyi Biotec plasma cell isolation kit ii
    Plasma Cell Isolation Kit Ii, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma cell isolation kit ii/product/Miltenyi Biotec
    Average 92 stars, based on 1 article reviews
    plasma cell isolation kit ii - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier
    plasma hepo protein  (R&D Systems)
    95
    R&D Systems plasma hepo protein
    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of <t>hEPO</t> mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), <t>and</t> <t>MCP-1</t> (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.
    Plasma Hepo Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma hepo protein/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    plasma hepo protein - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    plasma by elisa  (R&D Systems)
    94
    R&D Systems plasma by elisa
    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of <t>hEPO</t> mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), <t>and</t> <t>MCP-1</t> (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.
    Plasma By Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma by elisa/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    plasma by elisa - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    plasma p selectin  (R&D Systems)
    94
    R&D Systems plasma p selectin
    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of <t>hEPO</t> mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), <t>and</t> <t>MCP-1</t> (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.
    Plasma P Selectin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma p selectin/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    plasma p selectin - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    h post glucose loading plasma sparc  (R&D Systems)
    90
    R&D Systems h post glucose loading plasma sparc
    Change patterns of SPARC levels during OGTT at baseline, 3 months, and 6 months. (a–c) Plasma SPARC levels are increased after 1-h <t>and</t> <t>2-h</t> stimulation of oral glucose intake in the three groups at baseline (a), while showing increasing trends at 3 months (b) and 6 months (c). Comparations were calculated by repeated-measures ANOVA, adjusting for sex, baseline age, baseline BMI, total energy intake, physical activity, smoking, and drinking. Post hoc pairwise comparisons between 0 h and 1 or 2 h were conducted with Bonferroni adjustment. For SPARC at baseline, n = 81 for the MD group, n = 81 for the TJD group, and n = 73 for the CD group. For SPARC at 3 months, n = 72 for the MD group, n = 73 for the TJD group, and n = 65 for the CD group. For SPARC at 6 months, n = 66 for the MD group, n = 61 for the TJD group, and n = 57 for the CD group.
    H Post Glucose Loading Plasma Sparc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/h post glucose loading plasma sparc/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    h post glucose loading plasma sparc - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    human plasma cell isolation kit ii  (Miltenyi Biotec)
    94
    Miltenyi Biotec human plasma cell isolation kit ii
    Change patterns of SPARC levels during OGTT at baseline, 3 months, and 6 months. (a–c) Plasma SPARC levels are increased after 1-h <t>and</t> <t>2-h</t> stimulation of oral glucose intake in the three groups at baseline (a), while showing increasing trends at 3 months (b) and 6 months (c). Comparations were calculated by repeated-measures ANOVA, adjusting for sex, baseline age, baseline BMI, total energy intake, physical activity, smoking, and drinking. Post hoc pairwise comparisons between 0 h and 1 or 2 h were conducted with Bonferroni adjustment. For SPARC at baseline, n = 81 for the MD group, n = 81 for the TJD group, and n = 73 for the CD group. For SPARC at 3 months, n = 72 for the MD group, n = 73 for the TJD group, and n = 65 for the CD group. For SPARC at 6 months, n = 66 for the MD group, n = 61 for the TJD group, and n = 57 for the CD group.
    Human Plasma Cell Isolation Kit Ii, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human plasma cell isolation kit ii/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    human plasma cell isolation kit ii - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of hEPO mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), and MCP-1 (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.

    Journal: bioRxiv

    Article Title: A Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from Toxicity

    doi: 10.64898/2026.04.07.716828

    Figure Lengend Snippet: (a) Schematic illustration of the dosing regimen for non-human primate (NHP) studies. Male cynomolgus monkeys (n = 3 per group, Macaca fascicularis, 3–5 years old) received intravenous administrations of hEPO mRNA-loaded HHES LNPs (0.05 or 0.25 mg/kg) at weeks 0, 2, and 4. (b) Serum hEPO protein levels measured at 3, 6, and 24 h after each administration, showing transient and reproducible protein expression following repeated HHES LNP dosing (n = 3 per group). (c) Body weight changes monitored throughout the study, showing no significant alterations after repeated administration (n = 3 per group). (d–f) Serum biochemical parameters including AST (d), ALT (e), and MCP-1 (f) measured to assess hepatic function and inflammatory responses (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). (g–i) Hematological parameters including platelet count (g), lymphocyte percentage (h), and neutrophil count (i) evaluated following repeated dosing (n = 3 per group; two-way ANOVA with post-hoc multiple comparisons: ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Data are presented as mean ± SEM.

    Article Snippet: ELISA kits were used to quantify plasma hEPO protein (DEP00; R&D Systems, Minneapolis, MN, USA) and MCP-1 (BMS631INST; Thermo Fisher Scientific, Waltham, MA, USA).

    Techniques: Expressing

    Change patterns of SPARC levels during OGTT at baseline, 3 months, and 6 months. (a–c) Plasma SPARC levels are increased after 1-h and 2-h stimulation of oral glucose intake in the three groups at baseline (a), while showing increasing trends at 3 months (b) and 6 months (c). Comparations were calculated by repeated-measures ANOVA, adjusting for sex, baseline age, baseline BMI, total energy intake, physical activity, smoking, and drinking. Post hoc pairwise comparisons between 0 h and 1 or 2 h were conducted with Bonferroni adjustment. For SPARC at baseline, n = 81 for the MD group, n = 81 for the TJD group, and n = 73 for the CD group. For SPARC at 3 months, n = 72 for the MD group, n = 73 for the TJD group, and n = 65 for the CD group. For SPARC at 6 months, n = 66 for the MD group, n = 61 for the TJD group, and n = 57 for the CD group.

    Journal: Life Metabolism

    Article Title: Predictive value of 1-hour postprandial SPARC levels on metabolic outcomes from Mediterranean diet adherence: results from a randomized controlled feeding study

    doi: 10.1093/lifemeta/loaf039

    Figure Lengend Snippet: Change patterns of SPARC levels during OGTT at baseline, 3 months, and 6 months. (a–c) Plasma SPARC levels are increased after 1-h and 2-h stimulation of oral glucose intake in the three groups at baseline (a), while showing increasing trends at 3 months (b) and 6 months (c). Comparations were calculated by repeated-measures ANOVA, adjusting for sex, baseline age, baseline BMI, total energy intake, physical activity, smoking, and drinking. Post hoc pairwise comparisons between 0 h and 1 or 2 h were conducted with Bonferroni adjustment. For SPARC at baseline, n = 81 for the MD group, n = 81 for the TJD group, and n = 73 for the CD group. For SPARC at 3 months, n = 72 for the MD group, n = 73 for the TJD group, and n = 65 for the CD group. For SPARC at 6 months, n = 66 for the MD group, n = 61 for the TJD group, and n = 57 for the CD group.

    Article Snippet: At baseline and follow-ups, fasting plasma SPARC, 1-h and 2-h post-glucose loading plasma SPARC were assessed by using the ELISA kits (DY941-05, R&D Systems) [ ].

    Techniques: Clinical Proteomics, Activity Assay